Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.75 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.75 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19747448 | 0.89 | AKR1B1 (0.80) | AKR1B1 | |
| SCHEMBL6894085 | 0.88 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL1589816 | 0.88 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8505122 | 0.85 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL29353641 | 0.85 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL49012 | 0.85 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL1590803 | 0.85 | AKR1B1 (1.00) | AKR1B1 | |
| Zopolrestat SCHEMBL8129027 | 0.85 | AKR1B1 (0.98) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL9740879 | 0.84 | AKR1B1 (0.77) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL361256 | 0.83 | AKR1B1 (0.71) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092566-A1 | Treatment of cancer with aldose reductase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-21 | — | — | US | claimed |
| US-20100016404-A1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2010-01-21 | — | — | US | claimed |
| EP-2032145-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | The Board of Regents of The University of Texas System (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008002678-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-03 | — | — | WO | claimed |
| EP-0880964-B1 | Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy | PFIZER (US) | 2004-09-29 | — | — | EP | claimed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| US-5990111-A | ADMINISTERING AN ALDOSE REDUCTASE INHIBITOR TO A HUMAN SUBJECT TO TREAT DIABETIC CARDIOMYOPATHY | PFIZER INC. (US) | 1999-11-23 | — | — | US | claimed |
| EP-0880964-A2 | Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy | PFIZER INC. (US) | 1998-12-02 | — | — | EP | claimed |
| US-5391551-A | Method of lowering blood lipid levels | PFIZER INC. (US) | 1995-02-21 | — | — | US | claimed |
| EP-0624369-A1 | Method of lowering blood lipid levels | PFIZER INC. (US) | 1994-11-17 | — | — | EP | claimed |
| EP-3050593-B1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | UNIV TEXAS (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2654749-B1 | METHODS FOR TREATING COPD | UNIV TEXAS (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3050593-A1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | The Board of Regents of The University of Texas System (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | disclosed |
| US-5391551-A | Method of lowering blood lipid levels | PFIZER INC. (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0624369-A1 | Method of lowering blood lipid levels | PFIZER INC. (US) | 1994-11-17 | — | — | EP | disclosed |
| EP-0222576-B1 | HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS | PFIZER INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4939140-A | ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1990-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1B1 5/4885AKR1B10 24/4885AKR1A1 11/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1B1 5/4885AKR1B10 24/4885AKR1A1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.